323 related articles for article (PubMed ID: 12134947)
1. Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of an acyloxyalkoxy-based cyclic prodrug of the opioid peptide DADLE.
Tang F; Borchardt RT
Pharm Res; 2002 Jun; 19(6):780-6. PubMed ID: 12134947
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of the coumarinic acid-based cyclic prodrug of the opioid peptide DADLE.
Tang F; Borchardt RT
Pharm Res; 2002 Jun; 19(6):787-93. PubMed ID: 12134948
[TBL] [Abstract][Full Text] [Related]
3. A modified coumarinic acid-based cyclic prodrug of an opioid peptide: its enzymatic and chemical stability and cell permeation characteristics.
Ouyang H; Tang F; Siahaan TJ; Borchardt RT
Pharm Res; 2002 Jun; 19(6):794-801. PubMed ID: 12134949
[TBL] [Abstract][Full Text] [Related]
4. Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa?
Tang F; Horie K; Borchardt RT
Pharm Res; 2002 Jun; 19(6):773-9. PubMed ID: 12134946
[TBL] [Abstract][Full Text] [Related]
5. Factors that restrict the intestinal cell permeation of cyclic prodrugs of an opioid peptide (DADLE): Part I. Role of efflux transporters in the intestinal mucosa.
Ouyang H; Chen W; Andersen TE; Steffansen B; Borchardt RT
J Pharm Sci; 2009 Jan; 98(1):337-48. PubMed ID: 18537149
[TBL] [Abstract][Full Text] [Related]
6. Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa?
Tang F; Horie K; Borchardt RT
Pharm Res; 2002 Jun; 19(6):765-72. PubMed ID: 12134945
[TBL] [Abstract][Full Text] [Related]
7. Acyloxyalkoxy-based cyclic prodrugs of opioid peptides: evaluation of the chemical and enzymatic stability as well as their transport properties across Caco-2 cell monolayers.
Bak A; Gudmundsson OS; Friis GJ; Siahaan TJ; Borchardt RT
Pharm Res; 1999 Jan; 16(1):24-9. PubMed ID: 9950274
[TBL] [Abstract][Full Text] [Related]
8. Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter.
Horie K; Tang F; Borchardt RT
Pharm Res; 2003 Feb; 20(2):161-8. PubMed ID: 12636153
[TBL] [Abstract][Full Text] [Related]
9. Transport characteristics of tryptanthrin and its inhibitory effect on P-gp and MRP2 in Caco-2 cells.
Zhu X; Zhang X; Ma G; Yan J; Wang H; Yang Q
J Pharm Pharm Sci; 2011; 14(3):325-35. PubMed ID: 21824448
[TBL] [Abstract][Full Text] [Related]
10. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
Taub ME; Podila L; Ely D; Almeida I
Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
[TBL] [Abstract][Full Text] [Related]
11. A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP.
Xiao L; Yi T; Chen M; Lam CW; Zhou H
Eur J Pharm Sci; 2016 Oct; 93():456-67. PubMed ID: 27586020
[TBL] [Abstract][Full Text] [Related]
12. Bidirectional transport of rhodamine 123 and Hoechst 33342, fluorescence probes of the binding sites on P-glycoprotein, across MDCK-MDR1 cell monolayers.
Tang F; Ouyang H; Yang JZ; Borchardt RT
J Pharm Sci; 2004 May; 93(5):1185-94. PubMed ID: 15067695
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the Utility of Canine Mdr1 Knockout Madin-Darby Canine Kidney I Cells in Permeability Screening and Efflux Substrate Determination.
Chen EC; Broccatelli F; Plise E; Chen B; Liu L; Cheong J; Zhang S; Jorski J; Gaffney K; Umemoto KK; Salphati L
Mol Pharm; 2018 Nov; 15(11):5103-5113. PubMed ID: 30222362
[TBL] [Abstract][Full Text] [Related]
14. In vitro characterization of ABC transporters involved in the absorption and distribution of liensinine and its analogs.
Yu L; Shen Q; Zhou Q; Jiang H; Bi H; Huang M; Zhou H; Zeng S
J Ethnopharmacol; 2013 Nov; 150(2):485-91. PubMed ID: 24036064
[TBL] [Abstract][Full Text] [Related]
15. Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening.
Ye D; Harder A; Fang Z; Weinheimer M; Laplanche L; Mezler M
Pharm Res; 2020 Sep; 37(10):194. PubMed ID: 32918191
[TBL] [Abstract][Full Text] [Related]
16. Functional characterization of peptide transporters in MDCKII-MDR1 cell line as a model for oral absorption studies.
Agarwal S; Jain R; Pal D; Mitra AK
Int J Pharm; 2007 Mar; 332(1-2):147-52. PubMed ID: 17097248
[TBL] [Abstract][Full Text] [Related]
17. Phenylpropionic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeation.
Gudmundsson OS; Nimkar K; Gangwar S; Siahaan T; Borchardt RT
Pharm Res; 1999 Jan; 16(1):16-23. PubMed ID: 9950273
[TBL] [Abstract][Full Text] [Related]
18. Factors that restrict intestinal cell permeation of cyclic prodrugs of an opioid peptide (DADLE): Part II. Role of metabolic enzymes in the intestinal mucosa.
Ouyang H; Chen W; Andersen TE; Steffansen B; Borchardt RT
J Pharm Sci; 2009 Jan; 98(1):349-61. PubMed ID: 18537150
[TBL] [Abstract][Full Text] [Related]
19. Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active ingredient in the root of Salvia miltiorrhiza Bunge.
Yu XY; Lin SG; Zhou ZW; Chen X; Liang J; Liu PQ; Duan W; Chowbay B; Wen JY; Li CG; Zhou SF
Curr Drug Metab; 2007 May; 8(4):325-40. PubMed ID: 17504222
[TBL] [Abstract][Full Text] [Related]
20. Characterization of P-glycoprotein mediated transport of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor, across MDR1-MDCK and Caco-2 cell monolayers.
Zhang Y; Benet LZ
Pharm Res; 1998 Oct; 15(10):1520-4. PubMed ID: 9794492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]